Artiva (ARTV) Director Laura Stoppel Receives 13,750-Share Option

What Happened
Laura Stoppel, a partner at RA Capital and a director of Artiva Biotherapeutics (ARTV), was granted a stock option covering 13,750 shares on 2026-09-08. The grant is reported as a derivative award at $0.00 per share (no cash paid). The option vests on the earlier of September 8, 2027 or the date of Artiva’s 2027 annual meeting, subject to her continuous service as a director.

Key Details

• Transaction date: 2026-09-08; transaction type: Award/Grant (code A); derivative instrument (option).
• Shares covered: 13,750; reported price: $0.00; total immediate cash value reported: $0.
• Vesting: earlier of Sept 8, 2027 or the 2027 annual stockholder meeting, conditioned on continuous director service.
• Ownership after transaction: beneficial ownership of the option and underlying shares is disclaimed by the reporting persons (see footnotes); the filing does not report personal ownership shares retained by Stoppel.
• Timeliness: Filing period and file date are the same (2026-09-08), so the report appears timely.

Context
This was a grant of an option (a derivative award), not an open‑market buy or sale. Footnotes clarify that RA Capital Management, L.P. (a 10% owner) is the adviser to several funds and that Dr. Stoppel holds the option for the benefit of those funds and a separately managed account; she is obligated to turn over any net cash or stock received on exercise to the adviser to offset advisory fees. As a result, the reporting persons disclaim beneficial ownership of the option and underlying common stock. This is an institutional/director compensation arrangement rather than a personal stock purchase.